ArticleMolecular therapy. Nucleic acids2025
Targeting olfactory receptor OR2AT4: An innovative aptamer-based treatment for hair growth promotion.
Article in Molecular therapy. Nucleic acids, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- The Emerging Role of Olfactory Receptors: From Genomics to Precision Medicine.Molecular diagnosis & therapy · 2026Review
- Extra-nasal odorant receptors: molecular mechanisms and therapeutic implications.Frontiers in physiology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Non-canonical functions of olfactory receptors, one of the largest families of GPCR receptors not confined to the olfactory system, include an intriguing role on hair physiology. Previous studies using odorant agonists of the Olfactory Receptor family 2 subfamily AT member 4 (OR2AT4) showed hair growth stimulation. To develop more effective topical or systemic treatments for hair growth by specifically activating this receptor, it is crucial to identify new molecules with potent and well-defined activity. Here, we present a significant advancement in targeted therapeutic strategies for hair loss through the identification of a highly specific DNA aptamer targeting OR2AT4. The selected aptamer, designed as Ap.OR2AT4.17, effectively prolonged the anagen phase of hair growth cycle in a valuable preclinical human organ culture model. Importantly, the identified OR2AT4 aptamer was shown to be functional, leading to enhanced OR2AT4 expression in hair follicles, increased proliferation of hair matrix keratinocytes, and significant hair shaft elongation in organ-cultured human hair follicles. Notably, aptamer treatment also upregulated LL-37 and human β defensin-3 antimicrobial peptide expression, highlighting its role as a microbiota-modulating compound. These findings underscore the OR2AT4 aptamer's potential as a novel, targeted therapy for hair loss disorders, marking a promising step forward in the field.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.